Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. reports developments across precision diagnostic consumer products, generative AI publishing and software, and related intellectual property. The company markets the KetoAir breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and it has described plans to extend breathalyzer technology into additional diagnostic uses.
Recurring company updates also cover Avalon Quantum AI LLC, the Catch-Up generative and agentic AI video platform, provisional patent filings for automated commentary systems, and technology collaborations supporting AI media infrastructure. Avalon news also includes capital-structure actions such as private placements, warrant issuances, debenture conversions, shareholder approvals, and Nasdaq compliance matters.
Avalon GloboCare (NASDAQ: ALBT) subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,892) on Feb 18, 2026 for an AI system that generates multiple audience-adaptive commentary video variants from a shared evidence framework while preserving factual integrity.
The platform is designed to tailor tone, pacing, and presentation by audience profile, collect performance data to refine strategies, and adapt outputs for short- and long-form formats, regional/regulatory requirements, and brand-safe distribution. Potential applications cited include personalized financial commentary, sports recaps, and marketing content.
Avalon GloboCare (NASDAQ: ALBT) announced conversion of the majority of its outstanding debentures from a June 2024 convertible note financing, strengthening its balance sheet and reducing overhang.
The financing had an aggregate principal of $2.8 million; $288,000 was repaid in cash and $2.6 million was converted into common stock, which the company believes has largely been sold. Avalon said the conversion improves financial transparency and supports its return to Nasdaq minimum stockholders' equity compliance while enabling progress on diagnostic and AI initiatives.
Avalon GloboCare (NASDAQ: ALBT) said subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,889) on Jan 16, 2026 for “Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary Videos.”
The filing describes an AI architecture that enforces evidence-linked generation, builds structured evidence graphs, detects source contradictions, applies uncertainty handling, and embeds traceability and audit metadata into video outputs to support editorial review, compliance validation, and accountability.
Avalon GloboCare (NASDAQ: ALBT) announced renewal of the U.S. FDA establishment registration for the KetoAir™ handheld breathalyzer (registration no. 3026284320). KetoAir measures breath acetone concentration (BrAce) using nanosensor technology to provide non-invasive metabolic and ketosis insights for users on ketogenic programs. Avalon plans a combined B2B and B2C launch for KetoAir via Catch-Up™, its generative AI short-form video SaaS, operated by Avalon Quantum AI, LLC. Marketing through Catch-Up™ is planned to begin in the second quarter of 2026 to support distribution, engagement, and adoption across enterprise and consumer channels.
Avalon GloboCare (NASDAQ: ALBT) announced it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement under Rule 5550(b) and is now in compliance with all continued listing standards. The previously scheduled Nasdaq Hearings Panel session was cancelled and Avalon’s common stock will remain listed and traded on Nasdaq.
The company said restoring compliance supports its ability to pursue growth initiatives, including launching marketing for a generative AI video platform and expanding precision diagnostics and strategic assets.
Avalon GloboCare (NASDAQ: ALBT) announced the acquisition of RPM Interactive and highlighted RPM CEO and Avalon board member Michael Mathews discussing RPM’s Catch-Up generative AI video platform in a Dec. 30, 2025 interview.
Catch-Up is described as a SaaS platform that automatically generates recap-style videos using generative AI and large language models, planned for licensing to content creators, media companies and brands across news, sports, finance, entertainment and other categories. Avalon intends to use the platform to support marketing for KetoAir, its FDA-registered breathalyzer for metabolic wellness. The interview is available on ProactiveInvestors.com and on YouTube.
Avalon GloboCare (NASDAQ: ALBT) acquired RPM Interactive in an all-stock merger completed Dec. 12, 2025, effected by merging RPM into newly formed subsidiary Avalon Quantum AI, LLC.
Avalon issued 19,500 shares of Series E preferred (stated value $1,000/share; total purchase price $19.5 million) convertible at $1.50/share subject to a 4.99% ownership cap and conversion restrictions until May 12, 2026 and shareholder approval requirements. The company said this transaction brings stockholders’ equity above the $2.5 million Nasdaq minimum. RPM’s Catch-Up SaaS short-form generative AI video platform will support marketing for KetoAir™ and other consumer products.
Avalon GloboCare (NASDAQ: ALBT) reported Q3 2025 progress for its KetoAir™ breathalyzer, highlighting a UK commercial launch on Sept 1, 2025, presentation at the London Health Optimization Summit on Sept 13–14, 2025, and a Nevada first‑responder program started in August 2025.
The four‑month Nevada POOL/PACT Holistic Health Reset enrolled 50 first responders using KetoAir™ for daily ketone monitoring; October mid‑program data showed individual metabolic improvements. KetoAir™ is FDA‑registered (Reg. No. 3026284320), measures breath acetone (BrAce), and is manufactured by Qi Diagnostics; device apps are available on Apple App Store and Google Play.
Avalon GloboCare (NASDAQ: ALBT) announced the launch of its KetoAir™ breathalyzer device in the United Kingdom, with sales beginning September 1, 2025 through www.KetoAir.uk. The FDA-registered device measures breath acetone concentration to track ketosis and fat metabolism for individuals following ketogenic diets.
The handheld device, manufactured by Qi Diagnostics Limited, features nano-sensor technology and is compatible with both iOS and Android platforms. This UK expansion follows the company's successful U.S. market launch, targeting users pursuing ketogenic lifestyles for weight management, athletic performance, or therapeutic purposes.
[ "Expansion into the UK market broadens geographic footprint", "Product targets growing ketogenic diet market segment", "Device offers cross-platform compatibility (iOS and Android)" ]Avalon GloboCare (NASDAQ: ALBT) has announced a wholesale distribution agreement between its subsidiary Q&A Distribution and Saga Health Corporation for the KetoAir™ breathalyzer device. The device will be integrated into Saga Health's Holistic Health Reset Program targeting first responders.
KetoAir™, registered with the FDA (#3026284320), is a handheld device that measures breath acetone concentration (BrAce) to monitor ketosis and fat metabolism. The device features nano-sensor technology, provides real-time insights, and is compatible with both iOS and Android platforms through dedicated mobile apps.